Belumosudil, also known as KD-025 and WHO11343, is an orally bioavailable inhibitor of ROCK-II that is greater than 200-fold selective over ROCK-I (IC50s = 105 nM and 24 µM, respectively). Belumosudil (SLx-2119; 40 µM) induces significant down-regulations of Tsp-1 and CTGF mRNA levels in PASMC. Belumosudil (KD025; 100, 200 or 300 mg/kg, i.p.) dose-dependently reduces infarct volume after transient middle cerebral artery occlusion. It is used in the treatment of Autoimmune Diseases. Belumosudil was approved in 2021 in USA To treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy
MedKoo Cat#: 414223
Name: Belumosudil mesylate
CAS#: 2109704-99-4 (mesylate)
Chemical Formula: C27H28N6O5S
Exact Mass: 0.0000
Molecular Weight: 548.62
Elemental Analysis: C, 59.11; H, 5.14; N, 15.32; O, 14.58; S, 5.84
The following data is based on the product molecular weight 548.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
